検索結果

Prof. Terumitsu Hasebe, Director of Global Vascular Co.,Ltd., will give a presentation at VIVA 2025 (Vascular InterVentional Advances), an international conference to be held in Las Vegas from November 2-5, 2025 (Pacific Time).   Prof. Hasebe will present the latest updates on the BioStealth™ Hybrid Drug-Eluting Stent (DES) and its ongoing pivotal clinical trial in the following session.   Presentation Information Session Title: World Insights Date & Time:  Monday, November 3, 2025, 11:15–11:22 (Pacific Time, U.S.) Venue:  Wynn Las Vegas | InnoSphere Presentation Title:  BioStealth™ Hybrid DES Delivers Superior Patency and Rapid Healing in BTK Arteries: Pivotal Clinical Trial Underway   About VIVA   * based on information from the official VIVA Foundation website VIVA (Vascular InterVentional Advances) is one of the world’s leading international conferences focusing on endovascular and peripheral vascular interventions. The event brings together vascular specialists, researchers, and industry professionals from around the globe to share the latest advances in technology, clinical research, and treatment strategies.   Event Overview Conference: VIVA 2025 (Vascular InterVentional Advances) Dates: November 2-5, 2025 (Pacific Time) Venue: Wynn Las Vegas, Las Vegas, Nevada, U.S. Organizer: VIVA Foundation URL: https://viva-foundation.org/

On Wednesday, October 29, 2025, at 1:00 p.m. JST, our company’s Founder, President & CTO, Shunto Maegawa, will speak at the “9th Medical Device Innovation in Kashiwanoha.” He will present Global Vascular’s business in the Startup Pitch session and serve as a panelist on the panel discussion “Challenges from Academia and Challenges in Global Expansion.”   Program Highlights Part 2: Medical Device Startup Pitch Overview: Business introduction presentations by startup companies Presenting companies: Ai-BrainScience Inc./ Epsilon Medical Inc. / IllumiMedical Inc./ SEGNOS Co., Ltd. / medimo Inc. / Global Vascular Co., Ltd. Part 3: Panel Discussion Theme: “Challenges from Academia and Challenges in Global Expansion” Moderators: Takashi Fukuyama, Partner at MedVenture Partners, Inc. , and Masaaki Ito, Deputy Director and Head of Medical Device Development Promotion at the National Cancer Center Hospital East Panelists: Hiroki Ishida, CTO of Epsilon Medical, Inc. , and Shunto Maegawa, Founder, President & CTO, of Global Vascular, Co., Ltd.   The "Medical Device Innovation in Kashiwanoha" symposium, led by the National Cancer Center Hospital East, aims to build a medical device innovation ecosystem in Kashiwanoha. This year's theme is "Global Expansion." Startups active in overseas markets, companies seeking international expansion, and supporting organizations will share their perspectives through pitch presentations and a panel discussion.   Event Overview Title: 9th Medical Device Innovation in Kashiwanoha Date and time: Wednesday, October 29, 2025, from 4:30 to 7:40 p.m. JST On-site networking: From 7:40 to 8:40 p.m., exclusively for in-person attendees Venue: KOIL, 6F 6F, Shops & Offices Building, Kashiwanoha Campus 148-2, 178-4 Wakashiba, Kashiwa, Chiba Hybrid event with simultaneous online streaming Registration: Advance registration is required via Peatix . Fee: Free (advance registration required). Organizers: National Cancer Center Hospital East / Organization for Small & Medium Enterprises and Regional Innovation, JAPAN , Kanto Regional Head Office / TX Entrepreneur Partners / Chiba Prefecture Support (planned): Ministry of Health, Labour and Welfare / Ministry of Economy, Trade and Industry / Kashiwa City / Chiba Industry Advancement Center Cooperation: Mitsui Fudosan Co., Ltd. / Life Science Innovation Network Japan / Tsukuba City URL: https://www.ncch-accel.ncc.go.jp/jp/ncce/division/next_mdi_center/event/2025/1029_9thMDI/20251029.html

Prof. Terumitsu Hasebe, Director of Global Vascular Co., Ltd., will give an oral presentation at TCT 2025, the Transcatheter Cardiovascular Therapeutics annual conference, to be held in San Francisco, United States, from October 25–28, 2025.   Prof. Hasebe will present the research findings in the following session.   Presentation Information Session Title:  Novel Therapies for Peripheral Vascular Disease – 2 Date & Time:  Monday, October 27, 2025, 1:00 – 2:00 PM (Pacific Time, U.S.) Venue: Moscone Center South, Exhibition Level, Station 7 | Halls B–C, San Francisco, CA, U.S. Presentation Title: Novel Hybrid Drug-Eluting BioStealth™ Stent for Below-the-Knee Lesions: Preclinical Results and Proposed Pivotal Clinical Trial   About TCT　 *based on information from the official CRF website TCT, the Transcatheter Cardiovascular Therapeutics, is organized by the Cardiovascular Research Foundation (CRF) and recognized as one of the world’s leading international conferences in the field of interventional cardiovascular medicine. Each year, experts, clinicians, and researchers from around the world gather to present and discuss the latest evidence and innovations in cardiovascular intervention.   Event Overview   Title: TCT 2025: the Transcatheter Cardiovascular Therapeutics 2025 Dates: October 25–28, 2025 (Pacific Time, U.S.) Venue: Moscone Center (North and South Buildings), San Francisco, CA, U.S. Organizer: Cardiovascular Research Foundation; CRF URL: https://www.tctconference.com/

At the CIRSE 2025 (Cardiovascular and Interventional Radiological Society of Europe)　international conference in Barcelona, Spain, from September 13-17, 2025, Dr. Shunto Maegawa, our company’s Director &, will present a poster. The poster will highlight the preclinical results of the BioStealth™, a hybrid drug-eluting stent technology for vascular interventions that is currently under development, as well as the protocol of its ongoing pivotal clinical trial. Presentation Information Presentation Number: P-0843 Title: Preclinical Results of a Novel Hybrid Drug-Eluting Stent for Below-the-Knee Arteries and Its Ongoing Pivotal Clinical Trial Protocol: "BioStealth" Stent Technology Presentation Format: Poster presentation (to be displayed in the poster hall during the conference) CIRSE is a globally recognized interventional radiology congress where researchers and clinicians gather to share the latest advancements. This congress provides an opportunity to disseminate our research findings broadly and foster greater understanding among healthcare professionals. Event Overview Title: CIRSE 2025 Dates: September 13–17, 2025 (local time) Venue: Barcelona International Convention Centre (CCIB), Barcelona Organizer: Cardiovascular and Interventional Radiological Society of Europe URL: https://cirse2025.cirse.org/ © CIRSE 2025 / Source: CIRSE Congress promo material

Global Vascular Co., Ltd. (Headquarters: Tokyo, Japan), a company developing a next-generation medical device specializing in the treatment of Peripheral Artery Disease (PAD) in the legs, has successfully raised a total of 1 billion yen in Series B funding. With this round, the company has raised a cumulative total of 2.77 billion yen since its founding. Investors in this round include Diamond Medino Capital Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., Sumitomo Mitsui Trust Bank, Limited, MITSUI SUMITOMO INSURANCE Venture Capital Co., Ltd., Medikit Co., Ltd., Fast Track Initiative, Inc., Tokyo University of Science Innovation Capital Co., Ltd., and Tokyo University of Science Investment Management Co., Ltd., among others. [About Global Vascular] Global Vascular Co., Ltd. is a deep tech startup that originated from a university-based medical engineering collaboration group. The company's mission is "Towards a Future Where Walking is Guaranteed." Led by representative directors Kenta Bito, Ph.D., and Shunto Maegawa, Ph.D., Global Vascular is dedicated to developing the world's first cutting-edge endovascular treatment (EVT) with a proprietary drug-eluting stent delivery system incorporating a uniquely biocompatible material. [Press Release on PR TIMES | June 30, 2025] https://prtimes.jp/main/html/rd/p/000000006.000121727.html For inquiries concerning this matter, please contact us via the form provided below: https://www.g-vasc.com/en/contact

Global Vascular Co., Ltd. is pleased to announce the appointment of Ryutaro Iwanami as External Auditor, effective June 17, 2025. His appointment will further support our efforts to enhance corporate value and reinforce governance as we pursue our mission of "delivering the latest treatments to patients as quickly as possible." Career & Professional Experience  Passed the CPA exam and joined a major audit firm, working primarily on audits and advisory services for globally expanding financial institutions Assigned to the firm’s New York office (2007–2008)  Upon returning to Japan, served as Senior Manager, leading domestic and international audit teams Led audit teams as Executive Officer at a venture company, overseeing both internal audit operations and cross-functional collaboration  Established Iwanami CPA Office in 2015, serving as Representative  Founded Iplus Advisory Co., Ltd. in 2016, serving as President & CEO  Currently engaged in advisory services in financial accounting, managerial accounting, and business management  Qualifications   Certified Public Accountant Licensed Tax Accountant

The 31st Annual Meeting of the Japanese Society for Endovascular Intervention was held on June 13–14, 2025, at the Okinawa Convention Center. Prof. Hasebe, Director of Global Vascular and Professor at Tokai University Hachioji Hospital, served as the meeting chair. This multidisciplinary conference brought together physicians and healthcare professionals from neurosurgery, cardiac and vascular surgery, and radiology. The event aimed to promote the exchange of knowledge and ideas and to foster professional relationships across disciplines, all under the shared theme of “Endovascular Intervention.”   Throughout the two-day program, sessions included presentations on surgical techniques from clinical settings, updates on the latest technologies and research, and a pitch event featuring medical startups, university hospitals, and investors. A live surgical broadcast was also held from Tokai University Hachioji Hospital, where Prof. Hasebe is based, providing real-time footage and expert commentary on operative procedures. Each session saw strong attendance over both days, contributing to a highly productive and meaningful academic meeting. The conference also featured two special guest lectures, including one delivered by our Scientific Advisor, Prof. Elazer R. Edelman. Special Lecture: • Elazer R. Edelman, M.D., Ph.D. (MIT / Harvard Medical School): “The Integration of Basic Science, Engineering and Clinical Insights on an International Scale Propel Biomedical Translational Research” • Rami Tzafriri, Ph.D. (CBSET, Inc.): “Neurovascular thrombectomy – CBSET’s use of autologous clot models to assess efficacy and chronic safety” Global Vascular took part in the corporate exhibition area as a startup in the field of endovascular intervention. For more details, please visit the official conference website: https://n-practice.co.jp/JSEI2025/index.html

The 31st annual meeting of the Japanese Society of Endovascular Intervention, chaired by our company’s director, Professor Hasebe, will take place at the Okinawa Convention Center from June 13 to 14, 2025. In addition to symposiums, presentations and live operation courses, this academic conference will also feature a pitch event that brings startup companies together with current investors and capitalists. Global Vascular will be exhibiting as one of the startups. Dates: June 13 - 14, 2025. Registration period: March 3 - June 14, 2025 Venue: Okinawa Convention Center (4-3-1 Mashiki, Ginowan City, Okinawa Prefecture) Chairman: Professor Terumitsu Hasebe (Department of Diagnostic Radiology/ Endovascular Intervention Center, Tokai University Hachioji Hospital) For further details, please see the annual meeting website below. https://n-practice.co.jp/JSEI2025/index.html

On February 14 ,2025, Ms. Naoko Ishihara was appointed as an outside auditor of our company. As an attorney-at-law, Ms. Ishihara has extensive experience and a proven track record in a wide range of fields, including intellectual property, M&A, startup support, venture capital investment, corporate law including intellectual property strategy and strategic business alliances, cross-border transactions, and dispute resolution. With Ms. Ishihara's appointment, the company will work to further improve its corporate value and strengthen its governance structure in order to achieve its mission of "delivering the latest treatments to patients as quickly as possible." We would like to thank you for your continued support in the future.

Dr. Matsuoka and Dr. Hasebe will be speaking at TCT 2024, the world's largest cardiovascular congress to be held October 27-30, 2024 (Washington, DC local time), to present the latest data on the stent delivery system under development. Sunday, October 27, 9:00 – 10:00AM Moderated Abstracts, Critical Limb Threatening Ischemia - 1 Pre-Clinical Data on a Novel Hybrid Drug-Eluting Stent with Nanocoating for Below-the-Knee Lesions: “Leave the Right Thing Behind” / Emi Matsuoka Kearon Wednesday, October 30, 11:00 – 11:30AM Moderated Abstracts, Peripheral Arterial and Venous Disease and Intervention - 4 The Novel Hybrid Nano-coating Ni-Ti stent for below-the-knee atherosclerotic disease: The Newest “Leave the Right Thing Behind” Concept / Terumitsu Hasebe https://tct2024.crfconferences.com/

The NAM-HLGC is a three-phase grant program that encourages innovation and scientific advances and breakthroughs that extend healthy life expectancy. The first phase, “Catalyst Phase,” is for new ideas that will contribute to extending healthy life expectancy. Our research was awarded 2024 Catalyst Phase. https://healthylongevitychallenge.org/winners/development-of-a-hybrid-nano-coated-nitinol-drug-eluting-stent-hybrid-des-for-small-atherosclerotic-lesions-in-below-the-knee-btk/

Dr. Hasebe, took the stage at CIRSE2024, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held from September 14 to 18, 2024 (Lisbon local time), to present on the latest development of our stent delivery system under development. Lecture Session: SP 476 – Peripheral and renal artery 2 September 16, 2024 Current developments on hybrid nano-coated ultrathin-Nitinol drug-eluting stents for below-the-knee atherosclerotic disease: embracing the 'Leave the Right Thing Behind' concept / Terumitsu Hasebe Poster Session: Impact of Combination of “Passive” and “Active” Coating for Below-the-knee Stents: Non-clinical Update of Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) for Below-the-knee Atherosclerotic Disease / Terumitsu Hasebe https://programme.cirse2024.cirse.org/speakers/55561